FINAL EXAM NATIONAL BOARD OF EXAMINATIONS
JUNE 2017

POSSESSION USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE
EXAMINATION HALL.
HEMATOLOGY
PAPER III
HEMAT/J/17/48/III
Time 3 hours
Max. Marks 100
Important instructions:
• Attempt all questions in order.
• Each question carries 10 marks.
• Read the question carefully and answer to the point neatly and legibly.
• Do not leave any blank pages between two answers.
• Indicate the question number correctly for the answer in the margin space.
• Answer all the parts of a single question together.
• Start the answer to a question on a fresh page or leave adequate space between two answers.
• Draw table/diagrams/flowcharts wherever appropriate.
Write short notes on:
1. Acute myeloid leukemia
Cytogenetics and molecular mutations, and their
implications in its management.
Management of an elderly 65 years) patient with AML.
MRD detection in AML.

2. Thrombosis:
What are causes of inherited thrombophilia?
What is INR?
Diagnosis and treatment of a case of acute pulmonary
embolism.

3. Chronic lymphocytic leukemia:
How is this diagnosed?
Newer treatment options in refractory CLL?
Prognostic factors in CLL.

4. Lymphomas:
How to diagnose double hit and double expressing
lymphoma?
Management of Angio-immunoblastic T cell
lymphoma(AITL).
Current management of Hodgkin's Lymphoma.

5. Hemophilia
What are causative mutations in hemophilia
Managing knee replacement in hemophilia A.
Newer F VIII preparation.

6. Acute lymphoblastic leukemia
MRD detection in ALL.
How does MRD determine the management of ALL?
Diagnosis and management of mixed phenotypic acute
leukemia.

P.T.O.
FINAL EXAM NATIONAL BOARD OF EXAMINATIONS
JUNE 2017

POSSESSION USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE
EXAMINATION HALL.
HEMATOLOGY
PAPER III
7. Multiple myeloma:
Evolving diagnostic criteria.
Prognostic factors.
Management strategies.

8. Myelodysplastic syndrome:
Prognostic scoring.
Role of erythropoietin stimulating agents (ESA).
Management of high risk MDS.

9. Anticoagulant therapy:
Monitoring of anticoagulant therapy.
Newer anticoagulants.
Heparin resistance.

10. Haploidentical stem cell transplantation:
What is this and its concept?
T cell replete versus T cell depleted haploidentical stem
cell transplantation.
What are donor specific antibodies how they are
detected and their relevance in haploidentical stem cell
transplantation?
What are National and International HLA registries
available in India?